Form 4: SOPHiA GENETICS CMO Philippe Menu Sells Shares
Statement of Changes in Beneficial Ownership
Chief Medical Officer Philippe Menu sold 1,600 shares of SOPHiA GENETICS SA as part of a pre-arranged trading plan.
Summary
- Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 1,600 ordinary shares on April 14, 2026.
- The shares were sold at a weighted average price of $4.9581 per share.
- The transaction was executed under a pre-established Rule 10b5-1(c) trading plan.
- Following the sale, the reporting person retains beneficial ownership of 266,996 ordinary shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 program and represents a small fraction of the officer's total holdings.
Positives
- The transaction was conducted under a pre-planned Rule 10b5-1(c) trading plan, which typically indicates the sale is for personal financial management rather than a reaction to non-public information.
Negatives
- The sale represents a reduction in the insider's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term investor sentiment.
Future Outlook
No specific forward-looking guidance regarding company performance was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard practice for executives in the biotechnology sector to manage personal liquidity and is generally viewed as neutral by institutional investors.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is the industry standard for corporate officers to avoid potential conflicts of interest regarding insider trading regulations.
Stakeholder Impact
- Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the officer's total ownership.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 04/14/2026 | Date of the reported share sale transaction. |
| 04/16/2026 | Date the Form 4 was signed and filed. |
Keywords
SOPHiA GENETICS, SOPH, Insider Trading, Form 4, Biotech, Philippe Menu
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.